JP2022523145A5 - - Google Patents

Info

Publication number
JP2022523145A5
JP2022523145A5 JP2021545857A JP2021545857A JP2022523145A5 JP 2022523145 A5 JP2022523145 A5 JP 2022523145A5 JP 2021545857 A JP2021545857 A JP 2021545857A JP 2021545857 A JP2021545857 A JP 2021545857A JP 2022523145 A5 JP2022523145 A5 JP 2022523145A5
Authority
JP
Japan
Prior art keywords
sequence
cdr
seq
chain
sequence described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021545857A
Other languages
English (en)
Japanese (ja)
Other versions
JP7492522B2 (ja
JP2022523145A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016949 external-priority patent/WO2020163564A2/en
Publication of JP2022523145A publication Critical patent/JP2022523145A/ja
Publication of JP2022523145A5 publication Critical patent/JP2022523145A5/ja
Priority to JP2024080881A priority Critical patent/JP7759996B2/ja
Application granted granted Critical
Publication of JP7492522B2 publication Critical patent/JP7492522B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021545857A 2019-02-06 2020-02-06 抗ｔｒｅｍ１抗体及び関連方法 Active JP7492522B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024080881A JP7759996B2 (ja) 2019-02-06 2024-05-17 抗ｔｒｅｍ１抗体及び関連方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962802161P 2019-02-06 2019-02-06
US62/802,161 2019-02-06
US201962889994P 2019-08-21 2019-08-21
US62/889,994 2019-08-21
PCT/US2020/016949 WO2020163564A2 (en) 2019-02-06 2020-02-06 Anti-trem1 antibodies and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024080881A Division JP7759996B2 (ja) 2019-02-06 2024-05-17 抗ｔｒｅｍ１抗体及び関連方法

Publications (3)

Publication Number Publication Date
JP2022523145A JP2022523145A (ja) 2022-04-21
JP2022523145A5 true JP2022523145A5 (https=) 2023-02-01
JP7492522B2 JP7492522B2 (ja) 2024-05-29

Family

ID=71947128

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545857A Active JP7492522B2 (ja) 2019-02-06 2020-02-06 抗ｔｒｅｍ１抗体及び関連方法
JP2024080881A Active JP7759996B2 (ja) 2019-02-06 2024-05-17 抗ｔｒｅｍ１抗体及び関連方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024080881A Active JP7759996B2 (ja) 2019-02-06 2024-05-17 抗ｔｒｅｍ１抗体及び関連方法

Country Status (20)

Country Link
US (1) US20250179185A1 (https=)
EP (1) EP3921344A4 (https=)
JP (2) JP7492522B2 (https=)
KR (1) KR20210126638A (https=)
CN (1) CN113748132B (https=)
AU (1) AU2020218525A1 (https=)
BR (1) BR112021015479A2 (https=)
CA (1) CA3128053A1 (https=)
CL (1) CL2021002075A1 (https=)
CO (1) CO2021010887A2 (https=)
CR (1) CR20210462A (https=)
DO (1) DOP2021000165A (https=)
IL (1) IL284818A (https=)
MX (1) MX2021009500A (https=)
PE (1) PE20212269A1 (https=)
PH (1) PH12021551903A1 (https=)
SG (1) SG11202108570SA (https=)
TW (1) TWI870382B (https=)
WO (1) WO2020163564A2 (https=)
ZA (1) ZA202210284B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260017009A (ko) 2023-04-21 2026-02-04 셀시우스 테라퓨틱스, 인코포레이티드 항-trem1 항체 제제, 조성물 및 이의 용도
WO2025201129A1 (zh) * 2024-03-28 2025-10-02 北京丹序生物制药有限公司 一种抗触发受体-1抗体或其抗原结合片段及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150376294A1 (en) * 2012-12-03 2015-12-31 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
JP6180663B2 (ja) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
DK3653221T5 (da) * 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
WO2017127933A1 (en) * 2016-01-29 2017-08-03 The Governing Council Of The University Of Toronto Frizzled protein-binding agents and methods of use thereof
WO2017152102A2 (en) * 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
KR20230119259A (ko) * 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2021506244A5 (https=)
TWI701259B (zh) ４﹘１ｂｂ抗體及其製備方法和應用
JP2023549555A5 (https=)
TWI769537B (zh) 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途
JP2022514734A5 (https=)
JP2020536543A5 (https=)
WO2018209701A1 (en) Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
JP7257971B2 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
JP7649744B2 (ja) Ｂｔｎ３ａ結合タンパク質及びその使用
AU2018218753A1 (en) Anti-GPRC5D antibody and molecule containing same
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
JP2019515646A (ja) Ｐｄ−ｌ１に対する結合メンバー
JP2021514973A5 (https=)
JP2021515806A (ja) 三重特異性抗原結合タンパク質
JP2018531219A (ja) Ｐｄ−ｌ１抗体
JP2018531219A6 (ja) Ｐｄ−ｌ１抗体
RS53072B (sr) Antitela za humani receptor programirane smrti pd-1
CN108948194B (zh) 一种新的ctla-4单克隆抗体
WO2022002033A1 (zh) 具有H2L2与HCAb结构的结合蛋白
CA3221866A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
JP2024523838A5 (https=)
JP2022523145A5 (https=)
US12577314B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
JP7652705B2 (ja) Ｂｔｎ２に対する特異性を有する抗体及びその使用
JP2025509702A (ja) ＧＰＣ３陽性悪性細胞を標的殺傷するための二重特異性ＧＰＣ３ｘＣＤ２８抗体およびＧＰＣ３ｘＣＤ３抗体ならびにそれらの組み合わせ